Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc.（RXRX）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
rxrx · 股价预测 · 10 位分析师（近3月）· FMP · 更新于 2026年6月8日
分析师评级与共识
基于过去 3 个月内 10 位华尔街分析师
Hold
10 位分析师
共识
评级分布
12 个月目标价
High
$11.00
Consensus
$8.25
+148.1% upside
Low
$5.50
Median: $8.25 · Last Close: $3.33
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
Consensus Target
$8.25
148.1% upside
High Target
$11
230.8%
Low Target
$5.5
65.4%
Current Price
$3.33
as of today
Based on analyst price targets, the RXRX stock price prediction for the next 12 months ranges from $5.5 to $11. The consensus RXRX price forecast of $8.25 implies 148.1% upside from the current price of $3.33.
短期股价预测
算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $3.49 | ↑ 5.00% |
1-day model range: $3.46–$3.52. Peak: $3.52 (+5.00%).
长期股价预测
年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $2 | -50.0% |
| 2028 | $1 | -63.8% |
| 2029 | $1 | -69.2% |
| 2030 | $1 | -71.8% |
| 2031 | — | -73.1% |
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · RXRX · Jun 8, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-14 | Morgan Stanley | Maintains | Equal Weight→Equal Weight |
| 2026-05-07 | Needham | Maintains | Buy→Buy |
| 2026-04-30 | JP Morgan | Maintains | Overweight→Overweight |
| 2026-02-26 | B of A Securities | Maintains | Neutral→Neutral |
| 2026-02-26 | Needham | Maintains | Buy→Buy |
| 2025-12-17 | JP Morgan | Upgrade ↑ | Neutral→Overweight |
| 2025-09-11 | Needham | Maintains | Buy→Buy |
| 2025-07-08 | Needham | Maintains | Buy→Buy |
| 2025-06-16 | Morgan Stanley | Maintains | Equal Weight→Equal Weight |
| 2025-05-06 | Needham | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Recursion Pharmaceuticals, Inc. (RXRX) stock. Of the recent 52 rating actions, 1 were upgrades and 2 were downgrades. 10 analysts currently cover RXRX.
分析师推荐趋势
RXRX analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$62M
↓ 44.8% YoY
Revenue Next Year
$61M
↓ 0.5% YoY
EPS This Year
$-1.57
EPS Next Year
$-0.92
↓ 41.1% YoY
EPS ForecastReported vs Estimated
Analysts forecast RXRX EPS of $-1.57 for the current fiscal year, based on estimates from 6 analysts. The RXRX revenue forecast is $62M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
RXRX 股价预测由两类独立数据源支撑：来自 10 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。RXRX 的共识目标价为 $8.25（+148.1% 上行空间），分析师共识为 Hold。
RXRX 的短期预测（明日）为 $3.49（+5.00%）。 RXRX 对 2027 年的股价预测均值为 $2。 RXRX 对 2030 年的预测区间为 $1–$1。
Recursion Pharmaceuticals, Inc. 在 NASDAQ 上市，代码 RXRX。RXRX 在 2027 年的整体展望偏中性/分化，在覆盖分析师中约 40% 对应 Hold 共识。
常见问题
RXRX 预测 · 8 个问题根据 10 位华尔街分析师，RXRX 的 12 个月平均目标价为 $8.25，最高 $11.00、最低 $5.50。若有图表，中位目标价可在上方查看。相对当前价 $3.33，隐含约 +148.1% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.